| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ANL3; ANG-5; FHBL2; ANGPT5 |
| WB Predicted band size | 54 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human ANGPTL3 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ANGPTL3抗体的3篇代表性文献，简要概括内容：
1. **文献名称**：*ANGPTL3 Inhibition with Evinacumab in Homozygous Familial Hypercholesterolemia*
**作者**：Raal FJ 等
**摘要**：该研究报道了单克隆抗体Evicanumab(靶向ANGPTL3)在纯合子家族性高胆固醇血症患者中的临床试验结果。结果显示，该抗体显著降低低密度脂蛋白胆固醇(LDL-C)水平，为难治性高脂血症提供了新治疗策略。
2. **文献名称**：*Antibody-mediated inhibition of ANGPTL3 reduces lipoprotein levels in mice and monkeys*
**作者**：Gusarova V 等
**摘要**：通过动物实验证明，抗ANGPTL3抗体可有效抑制ANGPTL3功能，降低小鼠和非人灵长类动物的甘油三酯和LDL-C水平，揭示了其通过调节脂蛋白代谢酶(LPL和EL)实现降脂的机制。
3. **文献名称**：*ANGPTL3 blockade with a human monoclonal antibody reduces atherosclerosis in mice*
**作者**：Dewey FE 等
**摘要**：研究显示，抑制ANGPTL3可通过降低动脉粥样硬化相关脂蛋白水平减缓小鼠模型中的斑块进展，提示抗ANGPTL3疗法在心血管疾病预防中的潜在应用价值。
4. **文献名称**：*Lipid-lowering effects of anti-ANGPTL3 antibody in dyslipidemic mice and non-human primates*
**作者**：Toth S 等
**摘要**：该文献报道了一种新型抗ANGPTL3抗体在遗传性高脂血症动物模型中的效果，证实其显著降低总胆固醇、甘油三酯及致动脉粥样硬化脂蛋白水平，且耐受性良好。
以上文献均聚焦于ANGPTL3抗体的药理机制及治疗潜力，涵盖基础研究到临床转化。
ANGPTL3 (angiopoietin-like protein 3) is a liver-secreted glycoprotein that regulates lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL), thereby modulating plasma triglyceride and cholesterol levels. Its role in lipid homeostasis has made it a promising therapeutic target for dyslipidemias, particularly in patients with familial hypercholesterolemia or refractory hypertriglyceridemia.
ANGPTL3-targeting monoclonal antibodies, such as evinacumab, bind to ANGPTL3 to block its inhibitory effects on LPL and EL. This mechanism enhances lipase activity, reducing circulating triglycerides and LDL cholesterol while increasing HDL cholesterol. Preclinical studies demonstrated that ANGPTL3 inhibition ameliorates atherosclerosis in animal models. Clinical trials confirmed its efficacy, with evinacumab receiving FDA approval in 2021 for homozygous familial hypercholesterolemia.
The development of ANGPTL3 antibodies reflects a shift toward novel lipid-lowering strategies beyond traditional statins or PCSK9 inhibitors. Their potential extends to treating metabolic syndromes and cardiovascular diseases linked to lipid dysregulation. Ongoing research explores broader applications, including combination therapies and genetic lipid disorders, underscoring ANGPTL3's significance as a multifunctional metabolic regulator.
×
